File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00404-021-06309-y
- Scopus: eid_2-s2.0-85127584972
- PMID: 35380278
- WOS: WOS:000779026100002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review
Title | The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review |
---|---|
Authors | |
Keywords | Asia Cost-effectiveness HPV vaccination Systematic review |
Issue Date | 2022 |
Citation | Archives of Gynecology and Obstetrics, 2022, v. 306, n. 1, p. 173-187 How to Cite? |
Abstract | Purpose: The aim of this study was to systematically review the cost-effectiveness of HPV vaccination in Asia. Methods: We performed a systematic review of papers indexed in PubMed, Scopus, and Web of Science covering the period from 1 January 2000 to 13 August 2020. Results: Sixteen studies were included in the review. Half of them (8 studies) evaluated the cost-effectiveness of HPV vaccination in high-income countries and regions (HICs) while the other eight studies were set in low- and middle-income countries and regions (LMICs). In HICs, the implementation of bivalent, quadrivalent and nine-valent HPV vaccination was all shown to be cost-effective. Most studies (7/8) also showed that it was cost-effective to implement bivalent, quadrivalent, and nine-valent HPV vaccines in LMICs. However, one study concluded that it was not cost-effective to implement bivalent HPV vaccination in Thailand. Conclusion: In general, the implementation of bivalent, quadrivalent and nine-valent HPV vaccination for adolescent girls was cost-effective in both high-income countries and regions and low- and middle-income countries and regions in Asia. Policy makers in HICs could consider expanding the target vaccinated population, while for LMICs it is essential to reduce HPV vaccine price to a level at which the implementation of HPV vaccination is cost-effective. |
Persistent Identifier | http://hdl.handle.net/10722/330785 |
ISSN | 2022 Impact Factor: 2.6 2020 SCImago Journal Rankings: 0.793 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhu, Ke | - |
dc.contributor.author | Tian, Yuke | - |
dc.contributor.author | Dong, Xiaomei | - |
dc.contributor.author | Akinwunmi, Babatunde O. | - |
dc.contributor.author | Zhang, Casper J.P. | - |
dc.contributor.author | Huang, Jian | - |
dc.contributor.author | Ming, Wai kit | - |
dc.date.accessioned | 2023-09-05T12:14:16Z | - |
dc.date.available | 2023-09-05T12:14:16Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Archives of Gynecology and Obstetrics, 2022, v. 306, n. 1, p. 173-187 | - |
dc.identifier.issn | 0932-0067 | - |
dc.identifier.uri | http://hdl.handle.net/10722/330785 | - |
dc.description.abstract | Purpose: The aim of this study was to systematically review the cost-effectiveness of HPV vaccination in Asia. Methods: We performed a systematic review of papers indexed in PubMed, Scopus, and Web of Science covering the period from 1 January 2000 to 13 August 2020. Results: Sixteen studies were included in the review. Half of them (8 studies) evaluated the cost-effectiveness of HPV vaccination in high-income countries and regions (HICs) while the other eight studies were set in low- and middle-income countries and regions (LMICs). In HICs, the implementation of bivalent, quadrivalent and nine-valent HPV vaccination was all shown to be cost-effective. Most studies (7/8) also showed that it was cost-effective to implement bivalent, quadrivalent, and nine-valent HPV vaccines in LMICs. However, one study concluded that it was not cost-effective to implement bivalent HPV vaccination in Thailand. Conclusion: In general, the implementation of bivalent, quadrivalent and nine-valent HPV vaccination for adolescent girls was cost-effective in both high-income countries and regions and low- and middle-income countries and regions in Asia. Policy makers in HICs could consider expanding the target vaccinated population, while for LMICs it is essential to reduce HPV vaccine price to a level at which the implementation of HPV vaccination is cost-effective. | - |
dc.language | eng | - |
dc.relation.ispartof | Archives of Gynecology and Obstetrics | - |
dc.subject | Asia | - |
dc.subject | Cost-effectiveness | - |
dc.subject | HPV vaccination | - |
dc.subject | Systematic review | - |
dc.title | The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s00404-021-06309-y | - |
dc.identifier.pmid | 35380278 | - |
dc.identifier.scopus | eid_2-s2.0-85127584972 | - |
dc.identifier.volume | 306 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 173 | - |
dc.identifier.epage | 187 | - |
dc.identifier.eissn | 1432-0711 | - |
dc.identifier.isi | WOS:000779026100002 | - |